Cybersecurity : IKOULA Adds ESET Solutions to Its Offer, to Strengthen Data Protection for Companies
With the resurgence of cyber-attacks, which are ever more violent and paralyzing for companies, IKOULA - a leading player in the IaaS (Infrastructure As A Service), dedicated servers and outsourcing market - is joining forces with ESET – a global leader in digital security – to offer companies a professional endpoint protection solution against ransomware and zero-day threats.
At a time when cyber-risks must be approached in the same way as all other business risks, IKOULA is strengthening its range of cyber-protection solutions, and now offers to its customers the ESET solution: a solution created to protect all company's workstations from a single interface, whether they are desktop computers, laptops, or mobile devices.
"At ESET, we have made the choice to include in our solutions not only Cloud sandboxing technology – that is to say blocking ransomware and zero-day threats - but also full disk encryption functionality, as well as advanced multi-layer technology", explains Bruno BONNY, Marketing Director of ESET France. “Protection against cyber-attacks is therefore comprehensive and optimal. »
"Companies' cybersecurity needs are constantly increasing", continues Jean-Pascal MACCHI, Managing Director of IKOULA. “By offering our customers ESET solution, we give them the keys to responding to these issues and protecting themselves against the risks that could affect their dedicated servers, but also their other devices, and by extension their activity. »
About IKOULA
Pioneer of Cloud Computing since 1998, IKOULA has its own Datacenters in France, as well as two subsidiaries, in Spain and the Netherlands. Placing people at the heart of its activity, IKOULA maintains a close relationship with its customers, and provides them with teams of experts available 24/7, to advise and support them in the choice of professional IT solutions.
Web hosting, cybersecurity, managed services, Cloud computing or even unified communication thanks to the support of its parent company SEWAN, everything is done to meet the needs of today's and tomorrow's businesses.
About ESET
For more than 30 years, ESET® has been providing enterprises across the globe with industry-leading IT security software and services, including endpoint detection and response, encryption and authentication, and comprehensive security services packages. With high-performing, easy-to-use solutions that cater to businesses of all sizes, ESET protects customers from increasingly sophisticated digital threats in an ever-evolving landscape. ESET delivers to the enterprise market the people, expertise, and cutting-edge technology required to keep businesses safe and running without interruption.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005005/en/
Contact information
Laurane VASSOR ARCARO
lvassorarcaro@ikoula.com
+33 1 84 01 02 69
Darina SANTAMARIA
darina.j@eset-nod32.fr
+33 01 55 89 08 88
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 09:00:00 EEST | Press release
Almirall, S.A. (ALM) a global biopharmaceutical company focused on medical dermatology today announced new long-term results from the POSITIVE study, presented as a late-breaker at the 34th Congress of the European Academy of Dermatology and Venereology 2025 (EADV) in Paris. POSITIVE is the first RWE study in dermatology to use the World Health Organization Well-Being Index (WHO-5) as a primary endpoint. The selection of the abstract as a late breaker at the EADV congress highlights the importance of the findings of the POSITIVE study and its unique approach to evaluating the long-term holistic impact of an advanced treatment in patients with moderate-to-severe psoriasis, a condition that profoundly impairs social, psychological, and physical quality of life, impacting overall well-being1. Two‑Year Real‑World Results from POSITIVE The 24-month, multinational, phase IV observational study enrolled 785 adult patients with moderate-to-severe plaque psoriasis across nine European countries
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 09:00:00 EEST | Press release
Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with confidence. This joint offering provides an end-to-end solution designed to meet evolving regulatory expectations, accelerate adoption
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 08:00:00 EEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
Merck Opens Climate-Neutral €150 Million Filter Manufacturing Facility in Ireland18.9.2025 08:00:00 EEST | Press release
Merck, a leading science and technology company, has opened today its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the company’s ambition to achieve climate neutrality by 2040. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917767425/en/ Merck's new Blarney site in Cork expands company's filter capacity, creating 200+ jobs by 2028 The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturing of vaccines and life-saving therapies, including monoclonal antibodies, and emerging modalities like cell and gene therapies. By localizing these capacities in Europe, Merck hopes to reduce cross-border dependencies for the company’s customers. “Ireland is a leading hub for biopharmaceutical manufacturing and innova
Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay18.9.2025 08:00:00 EEST | Press release
Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface skin cells stop performing at the same level, or “go to sleep,” causing fine lines, dehydration, and looser skin, in turn leading to skin looking and feeling less firm and more fragile.1 Skin Activator technology serves as a “wake-up call” to sleeping surface skin cells. The unique complex is powered by encapsulated CICA to help restore the skin’s moisture barrier to visibly plump and firm skin as well as microdosed mandelic acid to increase surface skin cell turnover to visibly reduce dull, uneven skin. In clinical trials, the Skin Activator Hydrating & Firming Lotion showed to be effective
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom